|
Jul 29
|
Why value investing has worked better outside the US
|
|
Jul 29
|
Rapid Expansion and Innovation Drive $36 Billion Global Point-of-Care Diagnostics Market, Says New Kalorama Report
|
|
Jul 29
|
EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues
|
|
Jul 29
|
Sarepta shares rebound after shipments of gene therapy Elevidys resume in US
|
|
Jul 29
|
North America Autoimmune Disease Diagnostics Market Report 2025-2033 Featuring Bio-Rad, Abbott, Roche, Quest Diagnostics, Thermo Fisher Scientific, BioMerieux, Myriad Genetics, Siemens Healthineers
|
|
Jul 28
|
EU-US trade deal could add up to $19 billion in pharma industry costs, analysts say
|
|
Jul 28
|
Tweedy Browne International Value Reduces Stake in Zurich Insurance Group AG by 74.44%
|
|
Jul 28
|
Pre-Q2 Earnings: Is AbbVie Stock a Portfolio Must-Have?
|
|
Jul 28
|
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
|
|
Jul 28
|
Sarepta Stock Rises Despite Downgrade and FDA Probe. The Crisis Explained.
|
|
Jul 28
|
FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys
|
|
Jul 28
|
Roche’s Alzheimer’s therapy shows continued benefit
|
|
Jul 28
|
Genentech and Roche Present New Insights in Alzheimer’s Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC
|
|
Jul 28
|
Roche presents new insights in Alzheimer’s disease research across its diagnostics and pharmaceutical portfolios at AAIC
|
|
Jul 25
|
Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS
|
|
Jul 25
|
Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe
|
|
Jul 25
|
RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?
|
|
Jul 25
|
Sarepta Therapeutics Acknowledges CHMP Negative Opinion for ELEVIDYS in the European Union
|
|
Jul 25
|
Sarepta stock falls after Elevidys fails to get backing by EU regulators
|
|
Jul 25
|
Roche provides regulatory update on Elevidys™ gene therapy for Duchenne muscular dystrophy in the EU
|